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Background: Autoimmune pulmonary alveolar proteinosis (aPAP) is caused by granulocyte/
macrophage-colony stimulating factor (GM-CSF) autoantibodies in the lung. Previously, we re-
ported that GM-CSF inhalation therapy improved alveolar-arterial oxygen difference and serum
biomarkers of disease severity in these patients. It is plausible that inhaled GM-CSF improves
the dysfunction of alveolar macrophages and promotes the clearance of the surfactant.
However, effect of the therapy on components in bronchoalveolar lavage fluid (BALF) remains
unclear.
Objectives: To figure out changes in surfactant clearance during GM-CSF inhalation therapy.
Methods: We performed retrospective analyses of BALF obtained under a standardized
protocol from the same bronchus in each of 19 aPAP patients before and after GM-CSF inhala-
tion therapy (ISRCTN18931678, JMA-IIA00013; total dose 10.5e21 mg, duration 12e24 weeks).
For evaluation, the participants were divided into two groups, high responders with improve-
ment in alveolar-arterial oxygen difference 13 mmHg (n Z 10) and low responders with
that < 13 mmHg (n Z 9).
Results: Counts of both total cells and alveolar macrophages in BALF did not increase during
the therapy. However, total protein and surfactant protein-A (SP-A) were significantly
decreased in high responders, but not in low responders, suggesting that clearance of surfac-
tant materials is correlated with the efficacy of the therapy. Among 94 biomarkers screened in
bronchoalveolar lavage fluid, we found that the concentration of interleukin-17 and cancer
antigen-125 were significantly increased after GM-CSF inhalation treatment.
Conclusions: GM-CSF inhalation decreased the concentration of total protein and SP-A in BALF,
and increase interleukin-17 and cancer antigen-125 in improved lung of autoimmune pulmo-
nary alveolar proteinosis.
ª 2011 Elsevier Ltd. All rights reserved.
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Pulmonary alveolar proteinosis (PAP) is a rare lung disease
characterized by excessive accumulation of surfactant
materials within alveolar spaces.1 Patients with autoim-
mune PAP, which consists 90% of the disease with 0.49 and
6.04 cases per million for the incidence and prevalence in
the general population of Japan, respectively,2 present
a high level of autoantibodies against granulocyte/
macrophage-colony stimulating factor (GM-CSF) in the
serum as well as in bronchoalveolar lavage fluid (BALF).3
GM-CSF autoantibodies (GM-Ab) neutralize the biological
activity of GM-CSF,4e6 impairing alveolar macrophage(AM)
mediated pulmonary surfactant clearance.7e10 Recently,
GM-Ab purified from a patient with autoimmune PAP was
demonstrated to reproduce PAP after transfer into
nonhuman primates treated with anti-CD20 monoclonal
antibody and cyclophosphamide for blocking xenogrophic
immune responses, indicating that GM-Ab directly causes
PAP.11
Based on studies using GM-CSF knockout mice and
a phase I pilot study of inhaled GM-CSF which demonstrated
that inhaled delivery of GM-CSF improved PAP,12e14 we
previously conducted a national, prospective, multicenter,
phase II trial evaluating inhaled GM-CSF in patients with
unremitting or progressive PAP.15 Of 35 patients who
completed the 6-month inhalation, 24 patients (62%)
improved with decrease in alveolar-arterial oxygen differ-
ence more than 10 mmHg. In these subjects, serum
biomarkers including a mucin-like glycoprotein KL-6, car-
cinoembryonic antigen A (CEA), and surfactant protein A
(SP-A), which are known to correlate with the diseaseseverity,12 decreased significantly during the therapy. The
area of ground-glass-opacity (GGO) in pulmonary high-
resolution CT also reduced.
As suggested by our pilot study,14 inhaled GM-CSF may
promote the terminal differentiation of AM, and thus,
activate surfactant clearance, and improve the oxygen
transfer. In the pilot study, we showed that the maturation
level of AM proceeded and the function was restored after
GM-CSF inhalation. However, no direct evidence for
improvement in the surfactant clearance by the therapy
has been shown in the previous studies. In this study, we
investigated the components in BALF which were obtained
from the same bronchus by the same operator of the same
institute before the start of and after the end of the GM-
CSF inhalation therapy period. Our study revealed that
aerosolized GM-CSF therapy decreased the concentration of
total protein and surfactant protein A in BALF, while other
biological markers, including cancer antigen-125 (CA125)
and interleukin-17 (IL-17), increased during the treatment.Methods
Patients and protocols
The present study retrospectively utilized BALF which was
collected as an optional evaluation procedure from the
patients that participated in a pilot study (1 patient), an
early phase II study (6 patients), and a multicenter phase II
trial (12 patients, registered as ISRCTN18931678, JMA-
IIA00013) of GM-CSF inhalation therapy described previ-
ously.14 In brief, patients who had lung biopsy or cytology
286 K. Ohashi et al.findings diagnostic for PAP, including elevated serum GM-Ab
levels and no improvement during twelve-week observa-
tion, entered the treatment periods. Recombinant human
GM-CSF dissolved in 2 ml of sterile saline was inhaled using
an LC-PLUS nebulizer with a manual interrupter valve
connected to a portable compressor (PARI GmbH, Starn-
berg, Germany). For the first pilot study, treatment con-
sisted of 12 treatment cycles (250 mg daily on days 1e7 and
no drug on days 8e14 per cycle, Leucomax; Novartis AG,
Switzerland, total dose of 21 mg). For the early phase II
study, the treatment period consisted of two successive six-
week periods. In the first period, patients received inhaled
GM-CSF at a dose of 125 mg daily. In the second six-week
period, patients received inhaled GM-CSF (Leukine; Ber-
lex, Seattle, WA) at a dose of either 125 mg/day if the
change in A-aDO2 was >10 mmHg, or 250 mg daily if it was
<10 mmHg. This corresponded to a total administration of
either 10.5 mg or 15.75 mg of GM-CSF during the treatment
period. For the multicenter phase II study, treatments
included high-dose GM-CSF administration (125 mg twice
daily on days 1e8, none on days 9e14, Leukine; Berlex,
Seattle, WA) for six two-week cycles, then low-dose
administration (125 mg once daily on days 1e4, none on
days 5e14) for six two-week cycles (total dose of 15 mg).
The clinical information that was obtained in each study
was compared with the results of BAL analysis.
The study was approved by institutional review boards
and the BAL procedures were performed after written
informed consent was obtained. The clinical information
obtained at the clinical studies was entered into a database
to be compared with the results of BAL analysis. Each study
was designed and monitored for data quality and safety by
a steering committee composed of the principal investi-
gator at each participating site.
BAL procedures
The steering committee edited a standard operational
procedure for BAL which all participating institutes fol-
lowed. Three 50 ml aliquots of normal saline were instilled
into and suctioned sequentially through a bronchus of the
right middle lobe under bronchoscope using standard
procedures. Each patient underwent the BAL procedure at
the same bronchus in the right middle lobe by the same
operator of the same institute within one week before the
start of, and after the end of the GM-CSF inhalation therapy
period according to the unified standard procedure
protocol. Three aliquots of retrieved BAL fluids were
collected but only the second and the third aliquots were
combined and sent to Niigata University Medical and Dental
Hospital and subjected to the centralized analysis. Cells
were stained by modified Wright-Giemsa staining (Diff
Quick) and 400 nucleated cells were counted differentially
in cytocentrifuge preparations. Two hundred alveolar
macrophages were photographed and evaluated for their
sizes using Image J software (NIH).
Analysis of biomarkers in BAL fluid proteins
BAL fluid aliquots were analyzed using a standard Multi-
Analyte Profile (MAP) panel of 94 human analytes(AntigenImmunoassay; Rules-Based Medicine, Inc., Austin, TX). This
assays permits simultaneous quantification of multiple ana-
lytes including chemokines and cytokines with minimal
sample volume. Concentrations of IL-17 were also measured
using Quantikine Human IL-17 Immunoassay kits according to
the manufacturer’s instructions (R&D Systems). Concentra-
tions of CA125 were also measured with chemiluminescent
enzyme immunoassay using Lumipulse Presto system (Fujir-
ebio Inc., Tokyo). Wemeasured total protein concentrations
of BALF samples using the dye-binding Bradfordmethod (Bio-
Rad Laboratories, Inc.). The IL-17 levels and the CA125 levels
were normalized to total protein levels in BALF and
expressed as pg per mg of BALF protein, or U per mg of BALF
protein, respectively.
Immunohistochemical localization of cancer
antigen 125 (CA125) and IL-17
CA125 and IL-17 were localized in the lung by immunohis-
tochemical staining on paraffin-embedded lung sections
from one aPAP patient or a control using amousemonoclonal
anti-human CA125 (Dako, Inc.) and goat polyclonal anti-
human IL-17(R&D Systems), as described previously.4
Control lung tissues were obtained from the normal lung
parenchyma of surgical specimens removed for the resection
of lung cancer nodules. Color development was performed
using 3-amino-9-ethyl carbazole (AEC) liquid substrate
chromogen (DAKO) for IL-17 and diaminobenzidine (DAB)
(Nichirei, Tokyo, Japan) for CA125.
Statistical analysis
Numerical results are presented as the mean  standard
error or the median  interquartile range. The c2 test was
used to evaluate proportions for variables between high
responders and low responders. Analysis of variance and
paired t test were used for comparisons between normally
distributed data before and after the treatment periods.
Comparisons of nonparametric data were made using the
Wilcoxon’s signed-rank test. For group comparisons, anal-
ysis of variance and Wilcoxon’s rank-sum tests were used.
The correlation coefficient was obtained using Spearman’s
correlation method. All p values reported are two-sided.
Analysis was performed using JMP software version 6.0.3.
Results
Demographic data of participants before treatment
Nineteen patients whose BALF was subjected to the study
did not differ from the 39 participants in the multicenter
phase II study of inhaled GM-CSF15 in clinical features
including age, gender, symptoms, smoking status, history of
dust exposure, pulmonary functions, and GM-Ab titer. The
19 participants improved significantly in various oxygena-
tion indices including symptoms, oxygen supplement
status, 6-min walking tests, and AaDO2. As the median of
AaDO2 improvement was 13 mmHg, we divide the partici-
pants in two groups, high responders (DAaDO2  13 mmHg,
n Z 10) and low responders (DAaDO2 < 13 mmHg, n Z 9),
GM-CSF inhalation and BAL fluid in PAP 287based on the AaDO2 improvement to evaluate the corre-
lation of therapeutic response with clinical parameters.
There was no significant difference in demographic data
between the two groups (Table 1).
Serumbiomarkers including LDH, KL-6, CEA and SP-Awere
significantly improved, while SP-D were not altered (Table
2). The serum concentration of GM-CSF autoantibodies in
the 19 participants remained at similar levels throughout the
therapy. These results indicated that the patients in the
present study had similar backgrounds to the participants of
the previous phase II study15 and also demonstrated similar
improvement during GM-CSF inhalation.
Recovery rate of bronchoalveolar lavage
Recovery rate of saline instilled during branchoalveolar
lavage did not differ significantly (2.1  4.1%, 95%Table 1 Clinical Characteristics of patients with PAP.
Characteristic All patients
(n Z 19)
High resp
(AaDO2 >
(n Z 10)
n % Median
(I.Q. range)b
or mean  SE
n %
Age, years 19 54 (45e61) 10
Gender
Female 9 47 5 50
Male 10 53 5 50
Duration of
symptoms, months
19 17 (11e48) 10
Symptoms
Dyspnea 18 95 9 90
Cough 6 32 4 40
Sputum 4 21 3 30
Smoking status
Current smoker 4 21 3 30
Ex smoker 6 32 2 20
Never smoker 9 47 5 50
Dust exposure
Yes 6 32 4 40
No 13 68 6 60
Past lung lavage
(>6 mo prior to study)
Yes 8 42 3 30
No 11 58 7 70
Pulmonary Function
VC, % predicted 18 82.6  4.7 9
FEV1/FVC, % 18 86.1  1.5 9
DLCO, % predicted 18 57.5  4.4 9
PaO2, torr
f 19 55.0  1.9 10
PaCO2, torr
f 19 38.2  0.7 10
GM-CSF autoantibody,
mg/ml
19 21.5 (12.6e39.6) 10
a Comparison between high responders and low responders.
b Interquartile range is the range from the 25th to the 75th percen
c Calculated using the Wilcoxon’s rank-sum test.
d Calculated using the c2 test.
e Calculated using Student’s t test.
f Measured with patient in a supine position and breathing room airconfidence interval [CI]; 10.8 to 6.7) before and after GM-
CSF inhalation therapy (61.3  3.9% [95% CI 53.1e69.5] to
59.2  3.7% [95% CI 51.3e67.2]; nZ 16; pZ 0.62; paired t
test) (Table 2). The mean of the ratio between recovery
rates of before and after GM-CSF inhalation therapy in each
patient was 1.00  0.08 [95% CI 0.83e1.17], suggesting
intra-participant difference was not observed in recovery
rate.
Cellular changes in BALF during the treatment
To evaluate the effects of GM-CSF inhalation on BALF, we
first measured the cell counts. Due to the excessive accu-
mulation of amorphous materials in BALF of autoimmune
PAP, we managed to evaluate baseline cell counts in 16 out
of 19 participants in whom the data of BALF were available.
Total cell counts did not increase during the therapy.onders
13)
Low responders
(AaDO2 < 13)
(n Z 9)
P Valuea
Median
(I.Q. range)b
or mean  SE
N % Median
(I.Q. range)b
or mean  SE
56 (47.5e59.5) 9 53 (32.5e62) 0.39c
0.81d
4 44
5 56
14 (7e24.5) 9 32 (14e88.5) 0.06c
9 100 0.25d
2 22 0.40d
1 11 0.30d
0.41d
1 11
4 44
4 44
0.40d
2 22
7 78
0.26d
5 56
4 44
86.3  7.8 9 79.0  5.5 0.45e
87.6  2.3 9 84.8  2.1 0.38e
55.2  6.0 9 59.9  6.6 0.60e
52.5  2.2 9 57.7  3.1 0.18e
38.7  1.0 9 37.6  1.1 0.45e
20.4 (6.5e39.6) 9 24.2 (14.4e38.5) 0.54c
tiles of the distribution.
.
Table 2 Symptom, oxygen supplement, Exercise Tolerance, pulmonary function, serum biomarkers, and findings in bron-
choalveolar lavage fluid in patients with PAP before and after inhaled GM-CSF therapy.
Characteristic Before therapy After therapy P value
n % Mean  SE n % Mean  SE
Dyspnea <0.0001a
Yes 18 95 12 63
No 1 5 7 37
Oxygen supplement 0.023a
Yes 8 42 2 11
No 11 58 17 89
6 min walking testc
Walking distance (m) 12 418  37 12 474  24 0.10b
Minimal SpO2 (%) 12 83.5  1.8 12 89.8  1.9 0.005b
AeaDO2 mmHg
d 19 48.2  1.8 19 32.0  2.9 <0.0001b
Serum biomarkers of PAP
LDH (IU/l) 19 347  32.5 19 297  31.3 0.009b
CEA (ng/ml) 19 7.6  1.7 18 3.4  0.7 0.033b
KL-6 (U/l) 19 12527  2400 18 5521  1176 0.014b
SP-A (ng/ml) 19 138  18 18 101  15 0.011b
SP-D (ng/ml) 19 304  40 18 231  37 0.19b
GM-CSF autoantibody (mg/ml) 19 24.5  3.5 18 25.0  3.4 0.92b
BALF findings
Recovery rate (% of 150 ml saline) 16 61.3  3.9 16 59.2  3.7 0.62b
Cell Count ( 104 cells/ml) 16 19.1  3.2 17 29.0  4.8 0.098b
Macrophages ( 104 cells/ml) 16 11.3  2.0 17 20.9  3.7 0.029b
Lymphocytes ( 104 cells/ml) 16 6.5  1.5 17 7.6  2.0 0.64b
Neutrophils ( 104 cells/ml) 16 0.47  0.12 17 0.44  0.15 0.84b
Eosinophils ( 104 cells/ml) 16 0.039  0.021 17 0.063  0.035 0.54b
Macrophage size (mm2)
High Responders 6 545  76 6 531  83 0.90b
Low Responders 8 555  60 8 715  79 0.13b
a Calculated using the c2 test.
b Calculated using Student’s t test.
c Optional evaluation including 7 high responders and 5 low responders, of which change in AaDO2 was 15.5  2.9 and did not
significantly differ from that of the total 19 patients.
d Calculated using the following equation: A aDO2ZðPB  PH20 Þ  F1O2  PaCO2=Rþ fPaCO2  F1O2ð1 RÞ=Rg  PaO2.
PB; barometric pressure measured by local observatories, PH20 ; partial pressure of water vapor in inspired air (assumed to be 47 torr),
FIO2; fractional concentration of oxygen in dry gas (assumed to be 0.21), PaCO2; partial pressure of arterial CO2 measured in arterial
blood, R; respiratory quotient (assumed to be 0.8), PaO2; partial pressure of arterial oxygen measured in arterial blood.
288 K. Ohashi et al.However, macrophages significantly increased after the
therapy in the whole group (p < 0.05, n Z 16), but not
significantly in high responders (n Z 8) (Table 2). Base-line
counts of lymphocytes and neutrophils in high responders
were significantly higher than those in low responders
(Fig. 1A, B). However, the numbers of both neutrophils and
lymphocytes remained unchanged during the therapy
(Fig. 1A, B). Eosinophil numbers remained at baseline levels
during the therapy (Table 1) and no difference was
observed between high and low responders.
Changes in components in BALF
Subsequently, we characterized various markers in BALF for
the state of surfactant accumulation in the respiratory
tracts including total protein, phospholipids, and SP-A.
Total protein in high responders significantly decreased
(Fig. 1C). Phospholipids in BALFs showed a tendency to
decrease in high responders after the therapy, whileremaining at higher levels in low responders after the
therapy (Fig. 1D). Similarly, SP-A levels were higher in low
responders compared to high responders after the therapy
(Fig. 1E). Interestingly, SP-A in BALF improved significantly
in high responders during the therapy, although the serum
levels did not differ between high and low responders
(Fig. 1F). These results demonstrated that markers for the
state of surfactant accumulation were associated with the
improvement in oxygenation.
Changes of biomarkers in BALF
To evaluate the effects of GM-CSF inhalation on other
markers such as cytokines and epithelial markers in BAL
fluids, we performed a preliminary screening of 94
biomarkers on BALF from 10 patients using a microanalyte
system which revealed several candidates that could
predict the response to GM-CSF inhalation. The patients
comprised five high-responders and five low-responders,
1 patient 6 patients 12 patients
BAL analysis within 7 days before the start of treatment period 
Pilot Study Early Phase II Study Multicenter Phase II Study
Leucomax
12 cycles (24 weeks)
250 µg/day (d1-7)
no drugs (d8-14)
Total dose 21 mg
Leukine
6 weeks 
125 µg/day 
+
6 weeks
Leukine
6 cycles (12 weeks)
250 µg/day (d1-8)
no drug (d9-14) 
+
125 µg/day (1 patient)
or
250 µg/day (5 patients)
Total dose 
10.5 mg (1 patient)
or     
15.75 mg (5 patients)
6 cycles (12 weeks)
125 µg/day (d1-4)
no drug (d5-14)
Total dose 15 mg 
BAL analysis within 7 days after the end of the treatment period 
•
Figure 1 Profile of the study cohort.
GM-CSF inhalation and BAL fluid in PAP 289including one patient of the pilot study, five from the early
phase II study, and four from the multicenter phase II study.
Out of 94 biomarkers, levels of 62 markers were within
detectable ranges of the microanalyte system. Seventeen
markers increased more than two folds during the treat-
ment, but were not statistically significant probably due to
small scale of samples. The levels of other 45 markers did
not change during the treatment (Table 3). Base-line levels
of nine markers demonstrated significant correlation with
the improvement in AaDO2 (DAaDO2) (Table 4), from which
IL-17 and cancer antigen-125 (CA125) with correlation
coefficient of 0.756 and 0.739, respectively, were chosen
for further analyses. To confirm the production and locali-
zation of both IL-17 and CA125 in the lung of autoimmune
PAP, we first performed immunohistochemistry on paraffin
embedded lung sections from a patient and a control. AM
and lymphocyte-like mononuclear cells in the alveolar
spaces were frequently stained with anti-IL-17 antibody
(Fig. 3A), whereas no positive cell was observed in the
control lung (Fig. 3B). On the other hand, CA125 positive
staining was observed in the ciliated bronchial epitherial
cells in the autoimmune PAP, as in normal lungs of
a previous report27 (Fig. 3C). Then we determine the level
of these markers in the BALF using commercialized ELISA
kits. The levels of IL-17 tended to be higher in BALF of high
responders compared to low responders at baseline (0.083
and 0.037 pg/mg BALF protein for high and low responders,
respectively) and became significantly higher after the
therapy (0.34 and 0.052 pg/mg BALF protein for high and
low responders, respectively, Fig. 2G). Similarly, the levels
of CA125 were significantly higher in BALF of highresponders compared to low responders at baseline and
substantially increased after the therapy (Fig. 2H).Discussion
The present study demonstrated that GM-CSF inhalation
therapy decreased markers of surfactant accumulation,
including total protein and SP-A in the BALF of high
responders. Base-line CA125 levels and the counts of
lymphocytes and neutrophils were higher in high
responders than in low responders, while IL-17 levels were
higher in high responders after treatment, suggesting that
these markers may be candidates to predict the response to
GM-CSF inhalation. These results were based on the BALF
data which were normalized using total protein concen-
tration. As total protein decreased during GM-CSF therapy,
we attempted to undertake normalization using urea and
IgA concentrations, which produced comparable results.
There have been few previous reports on BALF of
patients with PAP who have undergone GM-CSF therapy.
Case reports showed that total protein and GM-CSF anti-
body (GM-Ab) decreased in BALF obtained from a PAP
patient who was treated with GM-CSF administered
subcutaneously.16,17 However, none of the open-labeled
trials of PAP patients treated with subcutaneous GM-CSF
administration have studied components in BALF.18e20
When examining GM-CSF inhalation, neither a report of
a child case,21 nor a retrospective study of 12 patients
treated with inhaled GM-CSF22 studied the change of
markers in BALF. We have previously characterized BALF
Table 3 Biomerkers which increased more than two fold
during GM-CSF inhalation treatment.
Post-therapy/
pre-therapy ratio
b-2 Microglobulin 2.18
Endothelin-1 2.11
Haptoglobin 2.69
IgA 5.18
IgM 2.48
IL-15 3.36
IL-16 2.46
IL-17 2.40
IL-18 4.18
IL-23 2.76
MCP-1 (monocyte chemoattractamt
protein 1; CCL2)
3.91
MDC (macrophage-derived
chemokine; CCL22)
6.27
MIP-1b (macrophage inflammatory
protein-1b; CCL4)
2.86
Myoglobin 3.24
OSM (Oncostatin M) 2.23
SHBG (sex hormone-binding globulin) 3.72
TNF RII (tumor necrosis
factor receptor II)
2.92
Following biomarkers did not change during the treatment: Alpha-
1 Antitrypsin, Adiponectin,a-2 Macroglobulin, a-Fetoprotein,
Apolipoprotein A1, Apolipoprotein CIII, Apolipoprotein H,
Complement 3, Cancer Antigen 125, Cancer Antigen 19e9, CD40,
CD40 Ligand, Carcinoembryonic Antigen, C Reactive Protein,
EGF(epidermal growth factor), EN-RAGE(extracellular newly
identified RAGE(receptor for advanced glycation end products)-
binding protein), Fatty Acid Binding Protein, Factor VII, Ferritin,
basic FGF(fibroblast growth factor), Fibrinogen, Glutathione S-
Transferase, ICAM-1(inter-cellular adhesion molecule 1), IGF-
1(insulin-like growth factor 1)IL-17E, IL-1beta, IL-1ra, IL-4, IL-8,
Lipoprotein (a), MIP-1alpha, Myeloperoxidase, PAI-1(plasminogen
activator inhibitor-1), Prostatic Acid Phosphatase, RANTES(regu-
lated upon activation, normal T-cell expressed, and secreted;
CCL5), Serum Amyloid P, Stem Cell Factor, Thyroxine Binding
Globulin, Tissue Factor, TIMP-1(tissue inhibitor of metal-
loproteinase 1), TNF-alpha, Thyroid Stimulating Hormone,
VEGF(Vascular endothelial growth factor), and von Willebrand
Factor.
Table 4 Biomerkers which demosntrataed correlation
with the improvement in AaDO2 (DAaDO2).
Ra P Valueb
IL-17 0.756 0.012
Cancer Antigen 125 0.739 0.015
C Reactive Protein 0.731 0.016
CD40 Ligand 0.712 0.021
IL-8 0.698 0.025
Complement 3 0.688 0.028
von Willebrand Factor 0.681 0.030
IL-15 0.653 0.041
Endothelin-1 0.652 0.041
a Spearman correlation coefficient.
b Values calculated using the Spearman correlation test.
290 K. Ohashi et al.and alveolar macrophages of three patients treated
successfully with inhaled GM-CSF, which was a predecessor
of this study.14
Although GM-Ab level remained stable,15 oxygenation
indices and clearance markers significantly improved during
the GM-CSF inhalation. To consider the mechanism of the
improvement of oxygenation, we should note that the total
amount of inhaled GM-CSF would be far less than the total
amount of GM-Ab. Using the Pari LC plus nebulizer, 10e20% of
inhaled GM-CSF was estimated to reach the peripheral
airspace in the lungs (12.5e25mg/day).23 GMeCSFeinhibitory
activity in BALF of aPAP was24.9 16.4 ng/mL,4 which was
estimated to be equivalent tomore than 150 mg of GM-CSF for
both lungs.Consequently, the amount of inhaled GM-CSF was
far less than the putative amount of GM-CSF to neutralize the
whole GM-Ab in a patient with PAP. In this regard, it is notable
PAP lesions are not evenly distributed, as indicated by the
geographic distribution of ground glass opacity in high-
resolution CT.24 Inhaled GM-CSF might first reach the mildly
impaired region in the lungs, rather than severely impaired
regions, and improve the function of the macrophages
present in those locations. The restored function of these
alveolar macrophages may contribute to improving the
clearance in the adjacent regions and the microstructure of
the lungs, such as pores of Kohn, could permit such a process.
This study suggested that IL-17 in BALF might be associ-
ated with the clinical response to GM-CSF inhalation. In this
regard, alveolar macrophages were reported to be a cellular
source of IL-17 in asthma.25 The report suggested that IL-17
is mainly produced by macrophages and not Th17 cells in
allergic inflammation related to asthma. GM-CSF inhalation
may stimulatemacrophages to augment the production of IL-
17, and thus, may be utilized as a marker of macrophage
function. Lymphocytes are known to be another source of IL-
17 in the lung26 and more lymphocytes were observed in
baseline BALF of high responders than that of low
responders. In addition, epithelial cells are likely to be
indirectly involved in the clearance of surfactantmaterial by
stimulating the maturation and function of alveolar macro-
phages, because CA125, reported to be produced by airway
epithelial cells,27 was associated with the improvement in
oxygenation. Alternatively, regenerating broncho-epithelial
cells might be associated with the clearance of surfactant
materials in lower respiratory tracts, thus, CA 125 might be
related to the treatment effectiveness.
In our previous pilot study, oxygenation indices improved
and total cell numbers in BALF were increased after the
GM-CSF inhalation. The functional evaluation of macro-
phages, including measures of phagocytic ability and the
expression of PU.1 and surface mannose receptors, were
restored to control levels after GM-CSF inhalation.14 In
contrast, the number of cells, especially alveolar macro-
phages, was not changed after inhalation in high responders
of this study. Furthermore, there was no significant
difference in the BALF data between participant of the 12-
week early phase II study and those of the 24-week multi-
center phase II study. The discrepancy between the
previous and present studies might be due to the limited
dose of GM-CSF (total 15 mg) compared to our pilot study
(total 21 mg). It will be worthy to evaluate macrophage
function in a future study using a randomized trial
comparing a high-dose regimen with a low-dose one.
A B
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Figure 2 The findings of BAL fluid obtained from high responders (high resp.) and low responders (low resp.) before therapy
(black bars) and after therapy (gray bars). The cell counts (A, B) and markers of clearance including total protein (C), phospholipid
(D), surfactant protein A (E) compared with serum levels of SP-A (F), IL-17(G) and CA125(H) are shown. Each bar represents the
mean (SE) for the designated patient [p < 0.05 (asterisk) and <0.01 (double asterisk) calculated using Wilcoxon’s signed-rank test
or Wilcoxon’s rank-sum test].
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Figure 3 Immunohistochemical detection of IL-17 (panel A
and B) and CA125 (panel C) in the lungs of autoimmune PAP
(panel A and C) and the normal lung (panel B). The arrows
mean the positively stained cells. Insets show higher
magnification of the cells of the lungs (left) and a BALF
sample (right) (X400).
292 K. Ohashi et al.Conclusions
We confirmed that GM-CSF inhalation decreased the
concentration of total protein and surfactant protein A in
BALF. We believe the data presented in this study will help
to delineate the mechanism of efficacy of GM-CSF inhala-
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